Fig. 1From: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaEnrollment, randomization, and completion. *Not treated n = 1, in GV-971 groupBack to article page